03/14/2024 3:31 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024 3:04 PM | Regeneron Pharmaceuticals (Issuer) STAHL NEIL (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/28/2024 3:04 PM | Regeneron Pharmaceuticals (Issuer) SING GEORGE L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/28/2024 3:04 PM | LAROSA JOSEPH J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/26/2024 3:34 PM | LAROSA JOSEPH J (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/26/2024 2:25 PM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/16/2024 3:15 PM | Regeneron Pharmaceuticals (Issuer) Van Plew Daniel P (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
02/13/2024 4:12 PM | Regeneron Pharmaceuticals (Subject) VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
02/09/2024 5:19 PM | Capital World Investors (Filed by) Regeneron Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/09/2024 11:22 AM | Fenimore Christopher R. (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/09/2024 8:49 AM | FMR LLC (Filed by) Regeneron Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/07/2024 4:59 PM | Landry Robert E (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/07/2024 4:07 PM | LAROSA JOSEPH J (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/05/2024 4:06 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/05/2024 3:05 PM | Regeneron Pharmaceuticals (Issuer) RYAN ARTHUR F (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/05/2024 8:16 AM | Regeneron Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/02/2024 6:16 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/01/2024 3:47 PM | Regeneron Pharmaceuticals (Subject) RYAN ARTHUR F (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2024 3:52 PM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/30/2024 4:02 PM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/25/2024 10:10 AM | JPMORGAN CHASE & CO (Filed by) JPMORGAN CHASE & CO (Filed by) Regeneron Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/25/2024 10:11 AM | JPMORGAN CHASE & CO (Filed by) JPMORGAN CHASE & CO (Filed by) Regeneron Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/23/2024 3:17 PM | GOLDSTEIN JOSEPH L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2024 5:30 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/04/2024 3:19 PM | Landry Robert E (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:19 PM | LAROSA JOSEPH J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:20 PM | Regeneron Pharmaceuticals (Issuer) YANCOPOULOS GEORGE (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:22 PM | Fenimore Christopher R. (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:15 PM | Regeneron Pharmaceuticals (Issuer) Thompson Craig B. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:16 PM | Guarini Kathryn (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:17 PM | Regeneron Pharmaceuticals (Issuer) Schenkein David P (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:17 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:06 PM | BROWN MICHAEL S (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:07 PM | GOLDSTEIN JOSEPH L (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:07 PM | Regeneron Pharmaceuticals (Issuer) SING GEORGE L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:08 PM | Regeneron Pharmaceuticals (Issuer) RYAN ARTHUR F (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/04/2024 3:10 PM | POON CHRISTINE A (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/03/2024 10:31 AM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/02/2024 3:28 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/02/2024 3:11 PM | Regeneron Pharmaceuticals (Subject) YANCOPOULOS GEORGE (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/27/2023 3:22 PM | BROWN MICHAEL S (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump’s “Tax Free” Retirement Strategy (Ad) Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value.
In other words, a dollar back then would buy $17.82 worth of goods in today's money.
If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… |
12/26/2023 3:08 PM | Fenimore Christopher R. (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/21/2023 3:22 PM | Fenimore Christopher R. (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/14/2023 3:10 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/14/2023 3:11 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2023 10:41 AM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/06/2023 3:02 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/15/2023 3:02 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/14/2023 3:02 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/07/2023 3:45 PM | Regeneron Pharmaceuticals (Subject) RYAN ARTHUR F (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/02/2023 6:10 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/02/2023 6:22 AM | Regeneron Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/01/2023 3:48 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2023 3:06 PM | Regeneron Pharmaceuticals (Issuer) Zoghbi Huda Y (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/13/2023 3:02 PM | Regeneron Pharmaceuticals (Subject) Zoghbi Huda Y (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2023 2:49 PM | Regeneron Pharmaceuticals (Subject) Tessier-Lavigne Marc (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/27/2023 3:05 PM | Decibel Therapeutics, Inc. (Subject) Regeneron Pharmaceuticals (Filed by)
| Form SC 13D/A | |
09/25/2023 7:48 AM | Decibel Therapeutics, Inc. (Subject) Regeneron Pharmaceuticals (Filed by)
| Form SC TO-T/A | |
09/12/2023 3:38 PM | Decibel Therapeutics, Inc. (Subject) Regeneron Pharmaceuticals (Filed by)
| Form SC TO-T/A | |
09/12/2023 3:01 PM | Regeneron Pharmaceuticals (Issuer) Schenkein David P (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
09/12/2023 3:03 PM | Guarini Kathryn (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/12/2023 3:04 PM | Regeneron Pharmaceuticals (Issuer) Schenkein David P (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/01/2023 3:14 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/25/2023 6:46 AM | Decibel Therapeutics, Inc. (Subject) Regeneron Pharmaceuticals (Filed by)
| Form SC TO-T | |
08/24/2023 3:27 PM | Regeneron Pharmaceuticals (Subject) Van Plew Daniel P (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/23/2023 4:06 PM | Landry Robert E (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/23/2023 3:52 PM | POON CHRISTINE A (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/22/2023 2:47 PM | Regeneron Pharmaceuticals (Subject) STAHL NEIL (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2023 11:27 AM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/18/2023 4:16 PM | Decibel Therapeutics, Inc. (Subject) Regeneron Pharmaceuticals (Filed by)
| Form SC 13D | |
08/10/2023 1:02 PM | Bassler Bonnie L (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/03/2023 5:56 AM | Regeneron Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/03/2023 5:48 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/03/2023 1:14 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2023 11:07 AM | Regeneron Pharmaceuticals (Subject) RYAN ARTHUR F (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/01/2023 3:23 PM | McCourt Marion (Reporting) Regeneron Pharmaceuticals (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/10/2023 3:08 PM | MURPHY ANDREW J (Reporting) Regeneron Pharmaceuticals (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/04/2023 6:11 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/04/2023 6:14 AM | Regeneron Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
04/17/2023 6:37 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/10/2023 6:01 AM | Regeneron Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |